Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

NCT ID: NCT03076970

Last Updated: 2019-12-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-03-21
• Study Completion Date: 2017-04-13

Brief Summary

This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of lasmiditan 200 mg.

Detailed Description

This is a randomized, double-blind, three-period, cross-over study to investigate the effect of single doses of sumatriptan (Imitrex) 100 mg on the pharmacodynamics of single doses of lasmiditan 200 mg. The study will last approximately 6 weeks including up to 3 weeks for screening and 22 days on study. Screening will be conducted within approximately 21 days of the first dose of study medication. Each dosing period will last 3 days (Day 1, Day 1, and Day 2). A wash-out period of 6 days will take place between each dose. The End of Study Visit (EoS) will take place 5 (+/- 2) days after the third dosing period is completed.

Conditions

Migraine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Lasmiditan 200 mg

single oral tablet

Group Type: EXPERIMENTAL

lasmiditan 200 mg

Intervention Type: DRUG

drug including single placebo tablet

matching placebo

Intervention Type: DRUG

single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.

Sumatriptan 100 mg

single oral tablet

Group Type: ACTIVE_COMPARATOR

Sumatriptan

Intervention Type: DRUG

drug including single placebo tablet

matching placebo

Intervention Type: DRUG

single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.

Combination of lasmiditan and sumatriptan

single oral tablet of each

Group Type: EXPERIMENTAL

lasmiditan 200 mg

Intervention Type: DRUG

drug including single placebo tablet

Sumatriptan

Intervention Type: DRUG

drug including single placebo tablet

Interventions

lasmiditan 200 mg

drug including single placebo tablet

Intervention Type: DRUG

Sumatriptan

drug including single placebo tablet

Intervention Type: DRUG

matching placebo

single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.

Intervention Type: DRUG

Other Intervention Names

LY573144

Eligibility Criteria

Inclusion Criteria

• Male or female aged 18-60 years, inclusive.
• Able and willing to give written informed consent.
• Body mass index (BMI) between 18 and 32 kilograms per square meter (kg/m²), inclusive.
• Participants must be able to refrain from consuming xanthine, quinine and caffeine containing beverages, and must refrain from prolonged intensive physical exercise during the study (from 72 hours prior to dosing until the end of study).
• Women must be:

• not pregnant
• not breast-feeding
• not planning to become pregnant during the study
• All females must have a negative serum pregnancy test at screening and a negative urine pregnancy test at check-in on Day -1 of each period. All women must agree to use an adequate method of contraception during the study and for 30 days following the end-of-study.
• Male participants must agree to utilize a highly effective method of contraception (condom plus spermicide) during heterosexual intercourse from clinic admission until 30 days following the end of study.
• Male participants must agree to refrain from sperm donation from clinic admission until at least 30 days following the end of study.
• Participants must be able to swallow multiple pills simultaneously.
• Participants must be able to understand the requirements of the study and must be willing to comply with the requirements of the study.

Exclusion Criteria

• Any medical condition, clinical laboratory test or other reason which in the judgment of the Investigator or designee makes the participant unsuitable for the study.
• Any clinically significant abnormalities (as determined by the Principal Investigator or designee) in hematology, blood chemistry and/or urinalysis lab tests at screening or at Period 1 D-1.
• Known hypersensitivity to lasmiditan, sumatriptan (Imitrex), or to any excipient of lasmiditan or sumatriptan (Imitrex) oral tablets.
• Use of any prescription medication, including monoamine oxidase A (MAO-A) inhibitors and other drugs associated with serotonin syndrome, within 14 days prior to dosing (except hormonal contraceptives) except for 5-HT1 (serotonin) agonists and selective serotonin reuptake inhibitors.
• History, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes including but not limited to angina pectoris, myocardial infarction, silent myocardial ischemia (Ischemic cardiac syndromes), stroke, transient ischemic attacks (cerebrovascular syndromes), and ischemic bowel disease (peripheral vascular disease).
• History, symptoms, or signs of vasospastic coronary artery disease.
• History, symptoms, or signs of arrhythmia or Wolff Parkinson White (WPW) syndrome that could affect the participant's safety in the opinion of the Investigator or designee.
• History, symptoms, or signs of severe hepatic impairment.
• History, symptoms, or signs of diabetes.
• History within the previous 3 years or current evidence of abuse (according to Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition [DSM-IV] criteria) of any drug, prescription or illicit, or alcohol; a positive urine screen for drugs of abuse or breathalyzer alcohol test.
• Positive urinary test for drugs of abuse and/or alcohol breath test at Screening and/or at check-in on Day -1 of each Period. Cotinine will be included at screening only.
• History of orthostatic hypotension with or without syncope.
• Supine systolic blood pressure (BP) > 135 millimeters of mercury (mmHg), diastolic BP > 85 mm Hg, respiratory rate >20 breaths per minute, pulse >90 beats per minute, or temperature >37.5º at Screening. Low values on any vital sign measurement will be assessed at the discretion of the Investigator or designee. For orthostatic vital signs, any decrease in systolic and/or diastolic blood pressure great than 20 mmHg. Any other changes will be assessed at the discretion of the Investigator or designee.
• Electrocardiogram (ECG) changes including QT interval prolongation and congenital long QT syndrome.
• Electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, or other medicinal products that lead to QT prolongation.
• Any clinically significant alanine aminotransferase (ALT), alkaline phosphatase (AP), aspartate aminotransferase (AST), or bilirubin abnormalities judged by the Investigator or designee at Screening.
• Treatment with centrally active drugs or those affecting peripheral cholinergic transmission within 3 months of study entry.
• Consumption of grapefruit, grapefruit juice, Seville oranges, Seville orange juice, or beverages containing any of these juices or consumption of members of the mustard green family (including kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, and mustard (i.e. seeds, greens, spice or the condiment)) within 72 hours of dosing.
• Tobacco or nicotine users except participants who stopped using tobacco or nicotine 1 year or more before signing the informed consent.
• Participant is at imminent risk of suicide or had a suicide attempt within 6 months prior to screening .
• Participation in any clinical trial of an experimental drug or device in the previous 30 days.
• Positive Hepatitis C antibody, Hepatitis B surface antigen, or positive human immunodeficiency virus (HIV) antibody.
• Participants who donated plasma in the 7 days or blood in the 3 months - Participants with an inability to communicate well with the Investigator or designee and study staff (i.e., language problem, poor mental development or impaired cerebral function).
• Inability to fast or consume the food provided in the study.
• Relatives of or staff directly reporting to the Investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

SNBL Clinical Pharmacology Center, Inc.

INDUSTRY

Sponsor Role: collaborator

CoLucid Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Eli Lilly and Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

SNBL Clinical Pharmacology Unit

Baltimore, Maryland, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

COL MIG-118

Identifier Type: OTHER

Identifier Source: secondary_id

H8H-CD-LAHI

Identifier Type: OTHER

Identifier Source: secondary_id

16885

Identifier Type: -

Identifier Source: org_study_id